Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide

Phase 2positiveruvonoflastsemaglutidePositive

AI Analysis

Summary

Rezera announced positive Phase 2 RESOLVE-2 results showing that the combination of ruvonoflast and semaglutide produced greater reductions in hsCRP compared to semaglutide monotherapy with a favorable safety and tolerability profile.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Combination of ruvonoflast and semaglutide produced greater reductions in hsCRP versus semaglutide monotherapy with favorable safety and tolerability profile

Importance:7/10

Sentiment:

0.75

Phase 2 resultscombination therapysafety datainflammatory markerhsCRP

Related Companies

$GCAN

Read the original article

Published by GlobeNewswire Clinical Studies on October 7, 2026 12:00 PM

Read Original